Humoral Immunity across the SARS-CoV-2 Spike after Sputnik V (Gam-COVID-Vac) Vaccination
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design, Participants and Serum Recollection
2.2. Antigens
2.3. ELISA Reactivity
(O.D. positive controls − O.D. negative controls)) × 100.
2.4. Surrogate Neutralization Test (SNT) Based on ACE2 Blocking Adsorption Immunoassay
2.5. Plaque Reduction Neutralization Test
2.6. Statistical Analysis
3. Results
3.1. Seroconversion Rates in Non-Exposed Vaccinated Individuals in the Clinical Trial
3.2. Reactivity to Different Regions of SARS-CoV-2 S
3.3. Surrogate Neutralization Test (SNT)
3.4. Plaque Reduction Neutralization Test (PRNT50)
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Barber, R.M.; Sorensen, R.J.D.; Pigott, D.M.; Bisignano, C.; Carter, A.; Amlag, J.O.; Collins, J.K.; Abbafati, C.; Adolph, C.; Allorant, A.; et al. Estimating Global, Regional, and National Daily and Cumulative Infections with SARS-CoV-2 through Nov 14, 2021: A Statistical Analysis. Lancet 2022, 399, 2351–2380. [Google Scholar] [CrossRef]
- Watson, O.J.; Barnsley, G.; Toor, J.; Hogan, A.B.; Winskill, P.; Ghani, A.C. Global Impact of the First Year of COVID-19 Vaccination: A Mathematical Modelling Study. Lancet Infect. Dis. 2022, 22, 1293–1302. [Google Scholar] [CrossRef] [PubMed]
- V’kovski, P.; Kratzel, A.; Steiner, S.; Stalder, H.; Thiel, V. Coronavirus Biology and Replication: Implications for SARS-CoV-2. Nat. Rev. Microbiol. 2021, 19, 155–170. [Google Scholar] [CrossRef]
- Wang, Q.; Zhang, Y.; Wu, L.; Niu, S.; Song, C.; Zhang, Z.; Lu, G.; Qiao, C.; Hu, Y.; Yuen, K.Y.; et al. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell 2020, 181, 894–904.e9. [Google Scholar] [CrossRef]
- Duan, L.; Zheng, Q.; Zhang, H.; Niu, Y.; Lou, Y.; Wang, H. The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens. Front. Immunol. 2020, 11, 576622. [Google Scholar] [CrossRef] [PubMed]
- Wheatley, A.K.; Pymm, P.; Esterbauer, R.; Dietrich, M.H.; Lee, W.S.; Drew, D.; Kelly, H.G.; Chan, L.J.; Mordant, F.L.; Black, K.A.; et al. Landscape of Human Antibody Recognition of the SARS-CoV-2 Receptor Binding Domain. Cell Rep. 2021, 37, 109822. [Google Scholar] [CrossRef] [PubMed]
- Ou, X.; Liu, Y.; Lei, X.; Li, P.; Mi, D.; Ren, L.; Guo, L.; Guo, R.; Chen, T.; Hu, J.; et al. Characterization of Spike Glycoprotein of SARS-CoV-2 on Virus Entry and Its Immune Cross-Reactivity with SARS-CoV. Nat. Commun. 2020, 11, 1620. [Google Scholar] [CrossRef]
- Cai, Y.; Zhang, J.; Xiao, T.; Peng, H.; Sterling, S.M.; Walsh, R.M.; Rawson, S.; Rits-Volloch, S.; Chen, B. Distinct Conformational States of SARS-CoV-2 Spike Protein. Science 2020, 369, 1586–1592. [Google Scholar] [CrossRef]
- Zhou, H.; Chen, Y.; Zhang, S.; Niu, P.; Qin, K.; Jia, W.; Huang, B.; Zhang, S.; Lan, J.; Zhang, L.; et al. Structural Definition of a Neutralization Epitope on the N-Terminal Domain of MERS-CoV Spike Glycoprotein. Nat. Commun. 2019, 10, 3068. [Google Scholar] [CrossRef]
- Wrapp, D.; Wang, N.; Corbett, K.S.; Goldsmith, J.A.; Hsieh, C.-L.; Abiona, O.; Graham, B.S.; Mclellan, J.S. Cryo-EM Structure of the 2019-NCoV Spike in the Prefusion Conformation. Science 2019, 367, 1260–1263. [Google Scholar] [CrossRef]
- Shah, P.; Canziani, G.A.; Carter, E.P.; Chaiken, I. The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic. Front. Immunol. 2021, 12, 637651. [Google Scholar] [CrossRef] [PubMed]
- Claro, F.; Silva, D.; Pérez Bogado, J.A.; Rangel, H.R.; de Waard, J.H. Lasting SARS-CoV-2 Specific IgG Antibody Response in Health Care Workers from Venezuela, 6 Months after Vaccination with Sputnik V. Int. J. Infect. Dis. 2022, 122, 850–854. [Google Scholar] [CrossRef] [PubMed]
- Chahla, R.E.; Tomas-Grau, R.H.; Cazorla, S.I.; Ploper, D.; Vera Pingitore, E.; López, M.A.; Aznar, P.; Alcorta, M.E.; Vélez, E.M.d.M.; Stagnetto, A.; et al. Long-Term Analysis of Antibodies Elicited by SPUTNIK V: A Prospective Cohort Study in Tucumán, Argentina. Lancet Reg. Health-Am. 2022, 6, 100123. [Google Scholar] [CrossRef] [PubMed]
- Polvere, I.; Parrella, A.; Zerillo, L.; Voccola, S.; Cardinale, G.; D’Andrea, S.; Madera, J.R.; Stilo, R.; Vito, P.; Zotti, T. Humoral Immune Response Diversity to Different COVID-19 Vaccines: Implications for the “Green Pass” Policy. Front. Immunol. 2022, 13, 833085. [Google Scholar] [CrossRef] [PubMed]
- Andreano, E.; Paciello, I.; Piccini, G.; Manganaro, N.; Pileri, P.; Hyseni, I.; Leonardi, M.; Pantano, E.; Abbiento, V.; Benincasa, L.; et al. Hybrid Immunity Improves B Cells and Antibodies against SARS-CoV-2 Variants. Nature 2021, 600, 530–535. [Google Scholar] [CrossRef]
- Claro, F.; Silva, D.; Rodriguez, M.; Rangel, H.R.; de Waard, J.H. Immunoglobulin G Antibody Response to the Sputnik V Vaccine: Previous SARS-CoV-2 Seropositive Individuals May Need Just One Vaccine Dose. Int. J. Infect. Dis. 2021, 111, 261–266. [Google Scholar] [CrossRef] [PubMed]
- Rodriguez-Nuñez, M.; Cepeda, M.D.V.; Bello, C.; Lopez, M.A.; Sulbaran, Y.; Loureiro, C.L.; Liprandi, F.; Jaspe, R.C.; Pujol, F.H.; Rangel, H.R. Neutralization of Different Variants of SARS-CoV-2 by a F(Ab′)2 Preparation from Sera of Horses Immunized with the Viral Receptor Binding Domain. Antibodies 2023, 12, 80. [Google Scholar] [CrossRef]
- Van Elslande, J.; Oyaert, M.; Lorent, N.; Vande Weygaerde, Y.; Van Pottelbergh, G.; Godderis, L.; Van Ranst, M.; André, E.; Padalko, E.; Lagrou, K.; et al. Lower Persistence of Anti-Nucleocapsid Compared to Anti-Spike Antibodies up to One Year after SARS-CoV-2 Infection. Diagn. Microbiol. Infect. Dis. 2022, 103, 115659. [Google Scholar] [CrossRef]
- Jaspe, R.C.; Sulbaran, Y.; Loureiro, C.L.; Moros, Z.C.; Marulanda, E.; Bracho, F.; Ramirez, N.A.; Canonico, Y.; D’Angelo, P.; Rodriguez, L.; et al. Detection of the Omicron Variant of SARS-CoV-2 in International Travelers Returning to Venezuela. Travel. Med. Infect. Dis. 2022, 48, 102326. [Google Scholar] [CrossRef]
- Logunov, D.Y.; Dolzhikova, I.V.; Shcheblyakov, D.V.; Tukhvatulin, A.I.; Zubkova, O.V.; Dzharullaeva, A.S.; Kovyrshina, A.V.; Lubenets, N.L.; Grousova, D.M.; Erokhova, A.S.; et al. Safety and Efficacy of an RAd26 and RAd5 Vector-Based Heterologous Prime-Boost COVID-19 Vaccine: An Interim Analysis of a Randomised Controlled Phase 3 Trial in Russia. Lancet 2021, 397, 671–681. [Google Scholar] [CrossRef]
- Jones, I.; Roy, P. Sputnik V COVID-19 Vaccine Candidate Appears Safe and Effective. Lancet 2021, 397, 642–643. [Google Scholar] [CrossRef] [PubMed]
- Logunov, D.Y.; Dolzhikova, I.V.; Zubkova, O.V.; Tukhvatullin, A.I.; Shcheblyakov, D.V.; Dzharullaeva, A.S.; Grousova, D.M.; Erokhova, A.S.; Kovyrshina, A.V.; Botikov, A.G.; et al. Safety and Immunogenicity of an RAd26 and RAd5 Vector-Based Heterologous Prime-Boost COVID-19 Vaccine in Two Formulations: Two Open, Non-Randomised Phase 1/2 Studies from Russia. Lancet 2020, 396, 887–897. [Google Scholar] [CrossRef] [PubMed]
- Fiolet, T.; Kherabi, Y.; MacDonald, C.J.; Ghosn, J.; Peiffer-Smadja, N. Comparing COVID-19 Vaccines for Their Characteristics, Efficacy and Effectiveness against SARS-CoV-2 and Variants of Concern: A Narrative Review. Clin. Microbiol. Infect. 2022, 28, 202–221. [Google Scholar] [CrossRef] [PubMed]
- Dimeglio, C.; Herin, F.; Martin-Blondel, G.; Miedougé, M.; Izopet, J. Antibody Titers and Protection against a SARS-CoV-2 Infection. J. Infect. 2022, 84, 248–288. [Google Scholar] [CrossRef]
- Voss, W.N.; Hou, Y.J.; Johnson, N.V.; Delidakis, G.; Kim, J.E.; Javanmardi, K.; Horton, A.P.; Bartzoka, F.; Paresi, C.J.; Tanno, Y.; et al. Prevalent, Protective, and Convergent IgG Recognition of SARS-CoV-2 Non-RBD Spike Epitopes. Science 2021, 372, 1108–1112. [Google Scholar] [CrossRef]
- Li, Y.; Lai, D.Y.; Zhang, H.N.; Jiang, H.W.; Tian, X.; Ma, M.L.; Qi, H.; Meng, Q.F.; Guo, S.J.; Wu, Y.; et al. Linear Epitopes of SARS-CoV-2 Spike Protein Elicit Neutralizing Antibodies in COVID-19 Patients. Cell Mol. Immunol. 2020, 17, 1095–1097. [Google Scholar] [CrossRef]
- Piccoli, L.; Park, Y.J.; Tortorici, M.A.; Czudnochowski, N.; Walls, A.C.; Beltramello, M.; Silacci-Fregni, C.; Pinto, D.; Rosen, L.E.; Bowen, J.E.; et al. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. Cell 2020, 183, 1024–1042.e21. [Google Scholar] [CrossRef]
- Ke, Z.; Oton, J.; Qu, K.; Cortese, M.; Zila, V.; McKeane, L.; Nakane, T.; Zivanov, J.; Neufeldt, C.J.; Cerikan, B.; et al. Structures and Distributions of SARS-CoV-2 Spike Proteins on Intact Virions. Nature 2020, 588, 498–502. [Google Scholar] [CrossRef]
- Heinz, F.X.; Stiasny, K. Distinguishing Features of Current COVID-19 Vaccines: Knowns and Unknowns of Antigen Presentation and Modes of Action. NPJ Vaccines 2021, 6, 104. [Google Scholar] [CrossRef]
- Bos, R.; Rutten, L.; van der Lubbe, J.E.M.; Bakkers, M.J.G.; Hardenberg, G.; Wegmann, F.; Zuijdgeest, D.; de Wilde, A.H.; Koornneef, A.; Verwilligen, A.; et al. Ad26 Vector-Based COVID-19 Vaccine Encoding a Prefusion-Stabilized SARS-CoV-2 Spike Immunogen Induces Potent Humoral and Cellular Immune Responses. NPJ Vaccines 2020, 5, 91. [Google Scholar] [CrossRef]
- Schroeder, J.T.; Bieneman, A.P. The S1 Subunit of the SARS-CoV-2 Spike Protein Activates Human Monocytes to Produce Cytokines Linked to COVID-19: Relevance to Galectin-3. Front. Immunol. 2022, 13, 831763. [Google Scholar] [CrossRef] [PubMed]
- Casalino, L.; Gaieb, Z.; Goldsmith, J.A.; Hjorth, C.K.; Dommer, A.C.; Harbison, A.M.; Fogarty, C.A.; Barros, E.P.; Taylor, B.C.; Mclellan, J.S.; et al. Beyond Shielding: The Roles of Glycans in the SARS-CoV-2 Spike Protein. ACS Cent. Sci. 2020, 6, 1722–1734. [Google Scholar] [CrossRef] [PubMed]
- Errico, J.M.; Adams, L.J.; Fremont, D.H. Antibody-Mediated Immunity to SARS-CoV-2 Spike. In Advances in Immunology; Academic Press Inc.: Cambridge, MA, USA, 2022; Volume 154, pp. 1–69. ISBN 9780323989435. [Google Scholar]
- Sealy, R.E.; Hurwitz, J.L. Cross-Reactive Immune Responses toward the Common Cold Human Coronaviruses and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Mini-Review and a Murine Study. Microorganisms 2021, 9, 1643. [Google Scholar] [CrossRef] [PubMed]
- Chen, Y.; Zhao, X.; Zhou, H.; Zhu, H.; Jiang, S.; Wang, P. Broadly Neutralizing Antibodies to SARS-CoV-2 and Other Human Coronaviruses. Nat. Rev. Immunol. 2023, 23, 189–199. [Google Scholar] [CrossRef] [PubMed]
- Ballmann, R.; Hotop, S.K.; Bertoglio, F.; Steinke, S.; Heine, P.A.; Chaudhry, M.Z.; Jahn, D.; Pucker, B.; Baldanti, F.; Piralla, A.; et al. ORFeome Phage Display Reveals a Major Immunogenic Epitope on the S2 Subdomain of SARS-CoV-2 Spike Protein. Viruses 2022, 14, 1326. [Google Scholar] [CrossRef]
- Wang, H.; Wu, X.; Zhang, X.; Hou, X.; Liang, T.; Wang, D.; Teng, F.; Dai, J.; Duan, H.; Guo, S.; et al. SARS-CoV-2 Proteome Microarray for Mapping COVID-19 Antibody Interactions at Amino Acid Resolution. ACS Cent. Sci. 2020, 6, 2238–2249. [Google Scholar] [CrossRef] [PubMed]
- Guo, L.; Lin, S.; Chen, Z.; Cao, Y.; He, B.; Lu, G. Targetable Elements in SARS-CoV-2 S2 Subunit for the Design of Pan-Coronavirus Fusion Inhibitors and Vaccines. Signal Transduct. Target. Ther. 2023, 8, 197. [Google Scholar] [CrossRef]
- Rastegar Kashkouli, A.; Jafari, M.; Yousefi, P. Effects of Gender on the Efficacy and Response to COVID-19 Vaccination; a Review Study on Current Knowledge. J. Ren. Endocrinol. 2022, 8, e25064. [Google Scholar] [CrossRef]
- Petrović, V.; Vuković, V.; Patić, A.; Marković, M.; Ristić, M. Immunogenicity of BNT162b2, BBIBP-CorV, Gam-COVID-Vac and ChAdOx1 NCoV-19 Vaccines Six Months after the Second Dose: A Longitudinal Prospective Study. Vaccines 2022, 11, 56. [Google Scholar] [CrossRef]
- Prather, A.A.; Dutcher, E.G.; Robinson, J.; Lin, J.; Blackburn, E.; Hecht, F.M.; Mason, A.E.; Fromer, E.; Merino, B.; Frazier, R.; et al. Predictors of Long-Term Neutralizing Antibody Titers Following COVID-19 Vaccination by Three Vaccine Types: The BOOST Study. Sci. Rep. 2023, 13, 6505. [Google Scholar] [CrossRef]
- Yang, T.-C.; Millar, J.; Groves, T.; Grinshtein, N.; Parsons, R.; Takenaka, S.; Wan, Y.; Bramson, J.L. The CD8+ T Cell Population Elicited by Recombinant Adenovirus Displays a Novel Partially Exhausted Phenotype Associated with Prolonged Antigen Presentation That Nonetheless Provides Long-Term Immunity. J. Immunol. 2006, 176, 200–210. [Google Scholar] [CrossRef] [PubMed]
- Tatsis, N.; Fitzgerald, J.C.; Reyes-Sandoval, A.; Harris-McCoy, K.C.; Hensley, S.E.; Zhou, D.; Lin, S.-W.; Bian, A.; Xiang, Z.Q.; Iparraguirre, A.; et al. Adenoviral Vectors Persist in Vivo and Maintain Activated CD8+ T Cells: Implications for Their Use as Vaccines. Blood 2007, 110, 1916–1923. [Google Scholar] [CrossRef] [PubMed]
- Hoehn, K.B.; Turner, J.S.; Miller, F.I.; Jiang, R.; Pybus, O.G.; Ellebedy, A.H.; Kleinstein, S.H. Human B Cell Lineages Associated with Germinal Centers Following Influenza Vaccination Are Measurably Evolving. Elife 2021, 10, e70873. [Google Scholar] [CrossRef] [PubMed]
- Turner, J.S.; Zhou, J.Q.; Han, J.; Schmitz, A.J.; Rizk, A.A.; Alsoussi, W.B.; Lei, T.; Amor, M.; McIntire, K.M.; Meade, P.; et al. Human Germinal Centres Engage Memory and Naive B Cells after Influenza Vaccination. Nature 2020, 586, 127–132. [Google Scholar] [CrossRef] [PubMed]
- Turner, J.S.; O’Halloran, J.A.; Kalaidina, E.; Kim, W.; Schmitz, A.J.; Zhou, J.Q.; Lei, T.; Thapa, M.; Chen, R.E.; Case, J.B.; et al. SARS-CoV-2 MRNA Vaccines Induce Persistent Human Germinal Centre Responses. Nature 2021, 596, 109–113. [Google Scholar] [CrossRef] [PubMed]
- Kim, W.; Zhou, J.Q.; Horvath, S.C.; Schmitz, A.J.; Sturtz, A.J.; Lei, T.; Liu, Z.; Kalaidina, E.; Thapa, M.; Alsoussi, W.B.; et al. Germinal Centre-Driven Maturation of B Cell Response to MRNA Vaccination. Nature 2022, 604, 141–145. [Google Scholar] [CrossRef] [PubMed]
- Laidlaw, B.J.; Ellebedy, A.H. The Germinal Centre B Cell Response to SARS-CoV-2. Nat. Rev. Immunol. 2022, 22, 7–18. [Google Scholar] [CrossRef] [PubMed]
- Chi, X.; Yan, R.; Zhang, J.; Zhang, G.; Zhang, Y.; Hao, M.; Zhang, Z.; Fan, P.; Dong, Y.; Yang, Y.; et al. A Neutralizing Human Antibody Binds to the N-Terminal Domain of the Spike Protein of SARS-CoV-2. Science (1979) 2020, 369, 650–655. [Google Scholar] [CrossRef]
- Finkelstein, M.T.; Mermelstein, A.G.; Miller, E.P.; Seth, P.C.; Stancofski, E.S.D.; Fera, D. Structural Analysis of Neutralizing Epitopes of the Sars-Cov-2 Spike to Guide Therapy and Vaccine Design Strategies. Viruses 2021, 13, 134. [Google Scholar] [CrossRef]
- Sheetikov, S.A.; Khmelevskaya, A.A.; Zornikova, K.V.; Zvyagin, I.V.; Shomuradova, A.S.; Serdyuk, Y.V.; Shakirova, N.T.; Peshkova, I.O.; Titov, A.; Romaniuk, D.S.; et al. Clonal Structure and the Specificity of Vaccine-Induced T Cell Response to SARS-CoV-2 Spike Protein. Front. Immunol. 2024, 15, 1369436. [Google Scholar] [CrossRef]
- Sterlin, D.; Mathian, A.; Miyara, M.; Mohr, A.; Anna, F.; Claër, L.; Quentric, P.; Fadlallah, J.; Devilliers, H.; Ghillani, P.; et al. IgA Dominates the Early Neutralizing Antibody Response to SARS-CoV-2. Sci. Transl. Med. 2021, 13, eabd2223. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Cornejo, A.; Franco, C.; Rodriguez-Nuñez, M.; García, A.; Belisario, I.; Mayora, S.; Garzaro, D.J.; Zambrano, J.L.; Jaspe, R.C.; Hidalgo, M.; et al. Humoral Immunity across the SARS-CoV-2 Spike after Sputnik V (Gam-COVID-Vac) Vaccination. Antibodies 2024, 13, 41. https://doi.org/10.3390/antib13020041
Cornejo A, Franco C, Rodriguez-Nuñez M, García A, Belisario I, Mayora S, Garzaro DJ, Zambrano JL, Jaspe RC, Hidalgo M, et al. Humoral Immunity across the SARS-CoV-2 Spike after Sputnik V (Gam-COVID-Vac) Vaccination. Antibodies. 2024; 13(2):41. https://doi.org/10.3390/antib13020041
Chicago/Turabian StyleCornejo, Alejandro, Christopher Franco, Mariajose Rodriguez-Nuñez, Alexis García, Inirida Belisario, Soriuska Mayora, Domingo José Garzaro, José Luis Zambrano, Rossana Celeste Jaspe, Mariana Hidalgo, and et al. 2024. "Humoral Immunity across the SARS-CoV-2 Spike after Sputnik V (Gam-COVID-Vac) Vaccination" Antibodies 13, no. 2: 41. https://doi.org/10.3390/antib13020041